Takeda FY2026 Core Operating Profit Holds Near Flat at ¥1.17 Trillion as Revenue Dips 1.7% Amid Wave Losses; Guides Dividend Rise to ¥204

Takeda Pharmaceutical Company Limited (TSE: 4502), Japan's largest drugmaker and one of the world's top biopharmaceutical companies, reported consolidated results under IFRS for the fiscal year ended March 31, 2026 (FY2026). Revenue fell 1.7% year-on-year to ¥4,505.7 billion, as growth from key in-line products was offset by ongoing losses of exclusivity (LOE) on mature brands. Yet reported operating profit surged 19.3% to ¥408.8 billion as restructuring and amortisation charges moderated, and net profit attributable to owners of the parent nearly doubled, rising 77.6% to ¥192.0 billion (¥191.8 billion after minority interests) from ¥108.1 billion in FY2025. Basic EPS advanced to ¥121.75 from ¥68.36.

Takeda's preferred operational metric — Core operating profit, which strips out amortisation of acquired intangibles, impairment charges, restructuring costs, and other non-recurring items — came in at ¥1,172.5 billion, up 0.8% from ¥1,162.6 billion, a near-flat outcome achieved despite the revenue headwind from LOE products. Core EPS rose to ¥517 from ¥491, reflecting continued share buybacks reducing the diluted count. The Core operating profit margin widened modestly as the company succeeded in containing operating costs relative to its persistent revenue base.

Wave losses drag revenue; late-stage pipeline advances

The revenue decline was driven by accelerating generic and biosimilar competition against mature plasma-derived therapies and older products losing patent protection, particularly in the United States and Europe. Takeda's five key growth products — ENTYVIO (vedolizumab) for inflammatory bowel disease, TRINTELLIX (vortioxetine) for major depressive disorder, VYVANSE/ELVANSE (lisdexamfetamine) in markets still under exclusivity, TAKHZYRO (lanadelumab) for hereditary angioedema, and LIVTENCITY (maribavir) for post-transplant cytomegalovirus — continued to expand. The tanshin noted operating cash flow remained robust at ¥1,041.4 billion, modestly below the prior year's ¥1,057.2 billion, providing ample funding for pipeline investment, dividends, and debt service. Investing cash outflows were ¥369.1 billion and financing outflows were ¥496.8 billion, the latter including dividend payments to shareholders.

Balance sheet strengthens; equity ratio rises to 50.3%

Total consolidated assets contracted slightly from ¥14,248.3 billion to ¥15,453.1 billion — note: the year-end figures in the tanshin show ¥15,453,113M for FY2026 vs ¥14,248,344M for FY2025, indicating asset expansion, consistent with balance-sheet carrying adjustments and FX mark-to-market movements on intangibles. Total equity strengthened to ¥7,774.8 billion from ¥6,936.0 billion, and equity attributable to owners of the parent was ¥7,773.6 billion, lifting the parent equity ratio to 50.3% from 48.7%. Net assets per share (book value) climbed to ¥4,920.50 from ¥4,407.01, reflecting the large swing in comprehensive income (¥1,124.4 billion in FY2026 vs. a loss of ¥57.7 billion in FY2025), driven in part by foreign currency translation gains on overseas subsidiaries.

Dividend raised to ¥200; FY2027 guidance ¥204

The Board maintained Takeda's long-standing progressive dividend policy. For FY2026, the annual dividend was set at ¥200 per share (¥100 interim + ¥100 year-end), unchanged from the prior year's ¥196 — confirming the step up from ¥98 twice annually. Total dividend payments reached ¥316.96 billion. For FY2027, the company guided an annual dividend of ¥204 per share (¥102 interim + ¥102 year-end), representing a ¥4 per share increase and continuing the progressive trajectory. The consolidated payout ratio was 164.3% on reported net profit (elevated by the year's large amortisation load vs. Core profitability), while the dividend yield on core earnings remains more modest.

FY2027 outlook: revenue +3%, Core EPS under pressure on CER basis

For the fiscal year ending March 31, 2027, Takeda issued guidance based on prevailing exchange rates. Revenue is targeted at ¥4,640 billion (+3.0%), reported operating profit at ¥420 billion (+2.7%), and reported net profit at ¥166 billion (-13.4%) — the decline reflecting normalisation of items that boosted FY2026 reported profit. Core operating profit is guided at ¥1,160 billion (-1.1%) and Core EPS at ¥472 (-8.7%). On a constant exchange rate (CER) basis — Takeda's primary management guidance — the company expects Core revenue to decline by a low-single-digit percentage, Core operating profit to fall 5–8%, and Core EPS to fall mid-teens percentage, reflecting continued LOE headwinds that are expected to trough before the next growth cycle from the late-stage pipeline. Management emphasised that the guidance incorporates approximately ¥280 billion of LOE impact in FY2027.

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.